As respiratory syncytial virus (RSV) season approaches, pediatric providers and health equity advocates are

facing a familiar dilemma: how to ensure that all infants-regardless of background or insurance status-receive

timely, potentially life-saving protection. New efforts across the country suggest the answer may lie not just in

science, but in systems.

A Shot That Could Change the Future

RSV is one of the most common causes of infant hospitalization in the United States, and in communities

already burdened by health inequities, it can be devastating. In 2023, the Centers for Disease Control and

Prevention (CDC) endorsed a new tool in the fight: Beyfortus® (nirsevimab-alip), an injectable monoclonal

antibody designed to protect infants during their most vulnerable RSV season.

The CDC recommends giving Beyfortus before babies are discharged from the hospital-a strategy that

eliminates follow-up challenges and boosts immunization rates. But as promising as this sounds, there’s a

catch: many hospitals lack a clear path to reimbursement, especially under the existing newborn “bundled

payment” system.

The Payment Problem

A recent article titled Protecting Newborns From RSV: Opening A Reimbursement Pathway highlights the

critical barrier posed by current payment models. The bundled payment for newborn care doesn’t account for

the additional cost of Beyfortus, leaving hospitals-especially those serving Medicaid and commercially

insured populations-reluctant to absorb the cost.

Health experts are now urging the creation of separate fee-for-service reimbursement mechanisms, arguing

that timely, hospital-based immunization can reduce downstream costs and health burdens, especially for

vulnerable populations.

A Success Story in Silicon Valley

Meanwhile, at Lucile Packard Children’s Hospital Stanford, a different story is unfolding. Following FDA

approval and recommendations from both the CDC and the American Academy of Pediatrics, the hospital

launched a universal Beyfortus immunization campaign.

By leveraging early stakeholder buy-in, cross-department collaboration, and streamlined logistics, the hospital

achieved an impressive 71% uptake among eligible infants prior to discharge. The campaign extended

across the newborn nursery, intermediate care nursery, and neonatal intensive care unit (NICU), and is now

being held up as a model for equitable implementation nationwide.

Equity Is Prevention

These efforts are more than operational-they are foundational to improving infant health in America’s

hardest-hit communities. By adapting reimbursement strategies and following proven implementation models,

health systems can help ensure every baby-regardless of race, income, or ZIP code-has a fair shot at a

healthy start.

Want to dive deeper into solutions for RSV equity?

Download the full RSV Health Equity Action Report and learn how policies and programs can align to deliver

prevention where it’s needed most.